Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are among the first classes of drugs approved for the treatment of type 2 diabetes mellitus (Bailey and Day, 2019). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.